HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced the execution of a Joint Venture agreement with Dalham, LLC (an affiliate company of The Health Network, Inc.). This agreement capitalizes on several years of research and development initiated by The Health Network (THN) for the establishment of cutting edge technologies associated with an individual’s mood, memory and mind development. THN spent over one (1) year developing an “all natural” energy drink before partnering with Dr. Kyl Smith. Dr. Smith has over seventeen (17) years experience in the study and development of cognitive enhancing products and programs founded on a platform of peer-reviewed scientific substantiation.
Dr. Smith is a #1 Best-selling Nutrition Inventor who is the architect behind the formulation, development and marketing of several products including a hundred-million dollar brand establishing an unprecedented industry benchmark through record sales. In addition, Dr. Smith is known for another unprecedented accomplishment: He acquired the first nutrient-based Qualified Health Claim for cognitive function to be approved in the FDA’s history. Ultimately he spent several years in research culminating in the book: Brighter Mind. This book is a compilation of his life’s work and resulted in the presentation of significant scientific advances in the area of cognitive function as substantiated thru peer-reviewed scientific literature. This scientific validation independently provided THN the basis to formulate a proprietary and advanced product focusing on brain function.
Ron Howell, stated “We feel proud and privileged to effectuate a Joint Venture with Dalham, LLC. This initiative will afford us the opportunity to continue our mission of providing 'break-through' technologies that will serve to improve an individual’s well being. To our knowledge, this product will be the first in the Functional Beverage category positioned as an 'all natural' energy 'Think Drink.' The scientific evidence supporting the ingredients will afford us the opportunity to create marketing literature that details the products contributions to cognitive function and overall health. The Joint Venture will provide the companies a high position of visibility with access to thousands of independent distributors serving communities in over 50 countries.”
Dr. Smith stated “This is the realization of a decade-long dream for me. The ability to introduce millions of people globally to products and programs that are based on ingredients that have been published in peer-reviewed science is the reason I have made this my life’s work and commitment to man-kind. To associate with a company that is willing to produce a product with the appropriate individual ingredients in keeping with the scientific evidence is something that few companies are willing to do. I am confident that the combination of my research and efforts with THN’s infrastructure will positively impact distribution on a global scale.”
The “soft launch” of this campaign is currently in production and scheduled to begin this month. It will involve radio and TV promotions incorporating customer-focused beneficial offers structured to motivate new customers to action. The offering will include the product and opportunity to acquire Dr. Smith’s book, Brighter Mind, to educate the user on the many scientifically validated benefits of foods, exercise and brain-based nutrition.
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.